Evotec's Science Keeps Delivering, but the Balance Sheet Is Writing a Different Story
Published on 09/19/2026 at 13:31 | Editorial boerse-global.de
Evotec's laboratory wins and its financial reality are moving in opposite directions — and right now, the market is only listening to the numbers.
On September 9, the Hamburg-based drug developer's subsidiary Just – Evotec Biologics reported a genuine breakthrough: an antibody program targeting orthopoxviruses, developed under contract for the U.S. Department of Defense, advanced into Phase I clinical testing. Government contracts of that caliber are hard evidence of the strength of the company's biologics platform. Yet the announcement barely registered against the weight of everything else on investors' minds.
A Share Base That Keeps Expanding
On Tuesday, Evotec disclosed a change in voting rights: following the issuance of subscription shares, the total number of voting rights climbed to 177,909,968. The move may be defensible on balance-sheet grounds, but the timing has landed badly. With the stock already under heavy pressure, every additional share acts as extra ballast.
The market's verdict has been unforgiving. Friday's close came in at a thin EUR 2.90, and just days earlier, on Tuesday, the stock touched a fresh 52-week low of EUR 2.77. Since the start of the year, the shares have shed 47 percent — a brutal re-rating for what was once a biotech market darling.
The Losses Run Deeper Than the Dilution
The dilution is only the visible symptom. The underlying problem sits in the operating accounts. Roughly three weeks ago, management confirmed a sharply reduced full-year outlook — and the stock has lost a further 13.8 percent since that confirmation.
Should investors sell immediately? Or is it worth buying Evotec?
For the full year 2026, Evotec now targets revenue of just EUR 570 million to EUR 610 million, well short of its original ambitions. The earnings picture is starker still: instead of an operating profit, the company expects an adjusted EBITDA of minus EUR 70 million to minus EUR 105 million.
The first half already set the tone. Revenue for the six-month period came in at EUR 300.1 million, a decline of 19.2 percent year over year, while the adjusted operating result (EBITDA) landed at minus EUR 42.7 million.
There has also been movement in the supervisory board. Camilla Macapili Languille, an independent member and part of the audit committee since June 2022, left the panel effective August 7. Changes in oversight bodies rarely happen by accident during a phase like this — and for investors, they offer little in the way of reassurance.
Partnerships Are Not a Share-Price Catalyst
Management has been trying to counter the gloom with operational progress, but the effect keeps fizzling out. A research collaboration with Plectonic Biotech, announced roughly two weeks ago, pairs Evotec's BiTCo platform with LOGIBODY technologies to go after solid tumors. Scientifically, it is a worthy combination. On the trading floor, however, what counts in the current climate is hard cash and dependable cash flows — not distant milestones.
Research alliances are, after all, the core business of a drug discovery company. But when the base segment is shrinking and the operating loss is widening, even innovative approaches struggle to build a floor under the stock. What shareholders want most is cost discipline and credible execution of the announced transformation.
A Test of Patience With No Quick Exit
Taken together, there is little to argue for a swift recovery in Evotec shares. The recent issuance of subscription shares has only deepened the skepticism. Until the company delivers hard proof in the coming quarters that the operating bleed can be stopped, the downside risks dominate.
For those already invested, the situation is sobering. Anyone betting on a bottom is catching a falling knife. Only when Evotec demonstrates that the lowered guidance marks the trough and that restructuring is taking hold is confidence likely to return to the market. Until then, the stock remains what it has been all year: an exhausting test of patience — with plenty of risk attached.
Ad
Evotec Stock: New Analysis - 19 September
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
